SP4 - SASKit
Clinical study of senescence-related and other biomarkers in pancreatic cancer patients compared to age- and sex-matched controls
Pancreatic cancer (pancreatic ductal adenocarcinoma, PDAC) is characterized by late clinical presentation, early metastases and poor prognosis, with a 1-year survival rate of only 15%. Recent developments in oncology have not shown much benefit in clinical trials of PDAC patients. Even in localized stages, PDAC appears as systemic disease: After successful resection of rare localized PDAC, many patients will show metastases within the first year.
As in cancer in general, in PDAC in particular there is an association to hypercoagulability: up to 34% of patients with metastatic PDAC develop thromboembolic complications. Whereas venous thromboembolism is the most common event and has been described for more than 100 years, more recently the association to arterial ischemic events, like stroke, has also been recognized. Still, the pathophysiology of this comorbidity is poorly understood.
This is a prospective, observational cohort study in patients with PDAC specifically in order to elucidate joint pathophysiology, and we maximized design overlap with subproject 5 (recruiting patients with stroke): 50 patients with PDAC are clinically characterized and followed regularly. Follow up will consist of demographic and clinical data, clinical tests, self-administered questionnaires and blood sampling. Routine blood parameters will be differential blood count, bilirubin, albumin, cholesterol, HbA1c, CRP, CA19-9, coagulation assays. Experimental blood analysis will consist of transcriptomics and proteomics in T cells and protein analysis in serum. Follow up is planned at 3 months, 6 months, 12 months, 24 months, 36 months and 48 months. Clinical important parameters are defined as endpoints: sarcopenia, deterioration of the performace status (ECOG) and quality of life. Comorbidity (that is vascular events) is one of the secondary endpoints. Patients living in the same household (e.g. spouses) will serve as a control group and be evaluated in the same way.
Together with subproject 5 omics data for three groups (PDAC patients, stroke patients, controls) will be available. Experimental blood analysis is done at the same research laboratory for all participants following standardized procedures. We also assist the computational groups with biomarker assessment and interpretation.
The study has been approved by the ethics committee of the University Rostock Medical Center.